Your session is about to expire
← Back to Search
Procedure
Surgical Tools for Breast Surgery Scarring (SCPPB Trial)
N/A
Recruiting
Led By Carol K Dingee, MD, FRCSC
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients having a total mastectomy with or without axilla surgical staging
Must not have
Patients having immediate breast reconstruction
Patients with a diagnosis of inflammatory breast cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months post-operatively
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to compare the appearance of scars after mastectomy surgery using different tools. The researchers want to see if there is any difference in how the scars look when using a scalpel, electroca
Who is the study for?
This trial is for patients undergoing a total mastectomy, with or without axillary surgical staging. It excludes those planning immediate breast reconstruction, diagnosed with inflammatory breast cancer, history of keloid scars or connective tissue disorders affecting the skin, prior incisions at the mastectomy site, known suture allergies, or current infections.
What is being tested?
The study compares cosmetic outcomes from using a scalpel, standard electrocautery, and PEAK PlasmaBlade for initial skin incisions in total mastectomies without immediate reconstruction. The goal is to determine if there's a difference in scar appearance and inform future equipment choices.
What are the potential side effects?
Potential side effects may include differences in scarring quality between methods used (scalpel vs. electrocautery vs. PlasmaBlade), wound infection risks associated with each tool type and postoperative pain variations.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have had or will have a complete breast removal surgery, with or without lymph node assessment.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am having immediate breast reconstruction.
Select...
I have been diagnosed with inflammatory breast cancer.
Select...
I have had surgery before at the site where my mastectomy is planned.
Select...
I currently have an infection.
Select...
I have a history of scleroderma or rheumatoid arthritis affecting my skin.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months post-operatively
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months post-operatively
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Scar cosmesis (SCAR scale)
Scar cosmesis (SCAR-Q)
Scar cosmesis (Vancouver Scar Scale)
Secondary study objectives
Delayed healing
Development of cellulitis
Development of excessive bruising
+10 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Standard ElectrocauteryExperimental Treatment1 Intervention
Standard electrocautery will be used for the entirety of the surgery, including the initial skin incision.
Group II: PEAK PlasmaBladeExperimental Treatment1 Intervention
The PEAK PlasmaBlade will be used for the entirety of the surgery, including the initial skin incision.
Group III: Standard of CareActive Control1 Intervention
The Standard of Care arm will consist of the scalpel for the initial skin incision and further randomization to have completion of the surgery with standard electrocautery or PEAK PlasmaBlade.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PEAK PlasmaBlade
2010
N/A
~70
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,481 Previous Clinical Trials
2,494,730 Total Patients Enrolled
5 Trials studying Postoperative Complications
132,020 Patients Enrolled for Postoperative Complications
Carol K Dingee, MD, FRCSCPrincipal InvestigatorProvidence Health Care, University of British Columbia